U.S. Markets closed
  • S&P 500

    +40.82 (+1.13%)
  • Dow 30

    +185.28 (+0.63%)
  • Nasdaq

    +156.37 (+1.28%)
  • Russell 2000

    +16.23 (+0.89%)
  • Crude Oil

    -0.94 (-2.07%)
  • Gold

    +38.20 (+2.15%)
  • Silver

    +1.52 (+6.75%)

    +0.0137 (+1.1468%)
  • 10-Yr Bond

    +0.0900 (+10.66%)
  • Vix

    +0.20 (+0.97%)

    +0.0100 (+0.7535%)

    -0.0170 (-0.0163%)

    -248.86 (-1.28%)
  • CMC Crypto 200

    -3.92 (-1.03%)
  • FTSE 100

    +118.54 (+1.89%)
  • Nikkei 225

    +353.92 (+1.34%)

Small Cap Pot Stocks Can Bring Investors High Profits-THC Therapeutics, Inc.

HENDERSON, NV / ACCESSWIRE / April 15, 2019 / No industry is growing faster than the global cannabis market. One small-cap stock in the space beginning to gain investor favor is THC Therapeutics, Inc. (THCT). Very recently, the company announced that it has received patent protection for the dHydronator® which can reduce moisture content of cannabis to 10% in only 10-14 hours (normally it takes up to 14 days). The US patent office has ALL 20 claims for The dHydronator®. The dHydronator® also destroys harmful surface contaminants & pathogens. The term of the patent provides 20 years of protection on the scalable intellectual property for the dHydronator®. This is big news from (THCT).

Today we are highlighting: THC Therapeutics, Inc. (THCT), Zenabis Global Inc. (ZBISF), Eve & Co Incorporated (EEVVF), Trulieve Cannabis Corp (OTC PINK: TCNNF) and Amphastar Pharmaceuticals, Inc., (AMPH).

THC Therapeutics, Inc. (THCT) (Market Cap: $146.259M; Share Price: $10.95) has developed a sanitizing herb dryer, The dHydronator®. Their laboratory-proven product is specifically designed for drying and sanitizing freshly harvested cannabis and herbs. THCT's product has been tested by two independent laboratories. The testing covered over 6 strains and 9 independent tests to confirm the findings.

As we mentioned earlier, the US patent office has accepted ALL 20 claims for The dHydronator®. The company has received patent protection for the dHydronator®. Start your research today on THCT.


Zenabis Global Inc. (ZBISF) (Market Cap: $284.096M; Share Price: $1.4980) recently announced the appointment of Michael Smyth as its new Chief Financial Officer, effective May 14, 2019 . The company also announced that it has now filed a final short form base shelf prospectus with the securities commissions in each of the provinces of Canada, except Québec, following the filing of its preliminary base shelf prospectus as announced in news on March 18, 2019.

Zenabis Global Inc. engages in the cultivation and sale of medical and recreational cannabis in Canada and internationally. The company provides its products primarily under the Zenabis and Namaste brands. It owns 3.5 million square feet of available production space in British Columbia, New Brunswick, and Nova Scotia. The company is headquartered in Surrey, Canada.


Eve & Co Incorporated (EEVVF) (Market Cap: $80.797M; Share Price: $0.361) recently announced that it has entered into an engagement letter with Haywood Securities Inc. pursuant to which the Underwriter has agreed to purchase 20,000,000 special warrants of the company, on a bought deal basis, at a price of $0.50 per Special Warrant for aggregate gross proceeds of $10 million. Closing of the Offering is expected to occur on or before May 10, 2019 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange, the securities regulatory authorities, and the satisfaction of other customary closing conditions. The company intends to use the net proceeds from the Offering for greenhouse expansion and for working capital and general corporate purposes.

Eve & Co, through its wholly-owned subsidiary Natural MedCo Ltd., holds cultivation and processing licenses under the Cannabis Act (Canada) for the production and sale of various cannabis products, including dried cannabis, cannabis plants and cannabis oil. Natural MedCo Ltd. was Canada's first female founded licensed producer of medicinal marijuana and received its cultivation license from Health Canada in 2016.

Eve & Co is led by a team of agricultural experts and has a licensed 220,000 sq. ft. scalable greenhouse production facility located in Middlesex County, Ontario with 32 acres of adjacent land for future expansion. Eve & Co has commenced construction of an additional 780,000 sq. ft. proposed expansion, bringing Eve & Co's total anticipated greenhouse capacity to 1,000,000 sq. ft.


Trulieve Cannabis Corp (TCNNF) (Market Cap: $1.446B; Share Price: $13.17) announced this week its financial results for the fourth quarter and full year ended December 31, 2018. Per the details of their announcement, it entered into agreements to acquire 100% of Life Essence, Inc. in Massachusetts and 100% of Leef Industries, LLC in California.

Trulieve is a vertically integrated "seed-to-sale" company and is the first and largest fully licensed medical cannabis company in the State of Florida. It operates as a medical marijuana company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as directly to patients via home delivery. It produces approximately 150 stock keeping units, including nasal sprays, capsules, concentrates, syringes, cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridge. As of March 14, 2019, the company operated 25 dispensaries.


Amphastar Pharmaceuticals, Inc., (AMPH) (Market Cap: $969.464M; Share Price: $20.72) announced last month that the U.S. Food and Drug Administration granted approval of its Abbreviated New Drug Application for Enoxaparin Sodium Injection 300mg/3mL Multiple Dose Vial. The company currently manufactures and distributes Enoxaparin Sodium Injection in prefilled syringe form and this approval of the Multiple Dose Vial allows the company to begin offering the full line of Enoxaparin products. Amphastar plans to launch Enoxaparin MDV in the second quarter of 2019.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.


Signed by

Priyanka Goel, CFA

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a three-month term consulting agreement with THCT dated 2/14/18. The agreement calls for 50,000 restricted shares of THCT per month. This agreement has been amended to $20,000 per month, and 55,000 shares per month and extended for twelve months ending 3/18/2020. All payments were made directly by THC Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. THCT was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Full Legal Disclaimer Click Here.

Contact Information:

Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States

SOURCE: ACR Communication LLC

View source version on accesswire.com: